IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.527
EU - Europa 650
AS - Asia 385
AF - Africa 70
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 3.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.489
FI - Finlandia 174
SG - Singapore 170
CN - Cina 119
IE - Irlanda 110
IT - Italia 107
NG - Nigeria 64
DE - Germania 57
NL - Olanda 44
CA - Canada 37
FR - Francia 37
SE - Svezia 37
IN - India 31
GB - Regno Unito 27
BE - Belgio 17
HK - Hong Kong 15
JP - Giappone 14
TR - Turchia 12
CZ - Repubblica Ceca 11
CL - Cile 7
EG - Egitto 6
IL - Israele 6
IR - Iran 6
AT - Austria 5
EU - Europa 5
KR - Corea 4
PT - Portogallo 4
RU - Federazione Russa 4
AU - Australia 3
BD - Bangladesh 3
UA - Ucraina 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BR - Brasile 2
ES - Italia 2
ID - Indonesia 2
NO - Norvegia 2
PL - Polonia 2
CH - Svizzera 1
DK - Danimarca 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
MD - Moldavia 1
MM - Myanmar 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
Totale 3.652
Salva come PNG Salva come JPEG
Città #
Chandler 516
Wilmington 409
Helsinki 174
San Mateo 162
Ann Arbor 131
Ashburn 119
Singapore 110
Dublin 109
Boardman 97
Shanghai 92
New York 86
Lawrence 82
Princeton 82
Leawood 77
Benin City 64
Amsterdam 41
Milan 40
Paris 36
Phoenix 35
Woodbridge 30
Seattle 23
Fairfield 22
Pune 18
London 17
Toronto 17
Brussels 15
Santa Clara 15
San Diego 14
Los Angeles 11
Kocaeli 9
Abbiategrasso 8
Andover 7
Montreal 7
Norwalk 7
Brno 6
Monmouth Junction 6
Munich 6
Redwood City 6
Cairo 5
Redmond 5
Umeda 5
Falls Church 4
Porto 4
Shenzhen 4
Tai Kok Tsui 4
Winnipeg 4
Florence 3
Hanover 3
Raleigh 3
Rome 3
Sacramento 3
Verona 3
Ariano nel Polesine 2
Beijing 2
Carrara 2
Changzhou 2
Chicago 2
Clearwater 2
Dhaka 2
Jakarta 2
Lambeth 2
Minatomirai 2
Montréal 2
Moscow 2
Noicattaro 2
Okayama 2
Olomouc 2
Palermo 2
Prague 2
Sherbrooke 2
Somma Vesuviana 2
São Paulo 2
Tappahannock 2
Vienna 2
Warsaw 2
Zhuhai 2
Ankara 1
Bengaluru 1
Borken 1
Brighton 1
Bucharest 1
Budapest 1
Caderzone 1
Cambridge 1
Central 1
Central District 1
Changchun 1
Chisinau 1
Chittagong 1
Chula Vista 1
Clifton 1
Concord 1
Copenhagen 1
Croydon 1
Daly City 1
Des Moines 1
Douglas 1
Eden Prairie 1
Edogawa 1
Egham 1
Totale 2.831
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 104
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 73
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 67
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 61
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 61
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 58
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 58
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 57
Biomarkers in Hepatocellular Carcinoma-Letter 56
COVID-19 and liver cancer clinical trials: not everything is lost 56
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 55
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 55
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 55
Cabozantinib for the treatment of hepatocellular carcinoma 54
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 54
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 53
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 53
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 53
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 51
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 51
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 50
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 49
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 49
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 49
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 48
Reply to Y. Pointreau et al 48
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 48
Role of liver biopsy in hepatocellular carcinoma 48
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 48
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 48
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 47
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 47
Shaping the landscape of immune oncology in hepatocellular carcinoma 46
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 46
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 46
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 46
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 45
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 44
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 43
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 43
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 43
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 42
Tivantinib for hepatocellular carcinoma 42
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 42
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 42
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 41
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 41
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 40
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 40
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 39
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 39
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 39
Regorafenib for the treatment of unresectable hepatocellular carcinoma 39
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 39
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 38
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 38
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 37
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 36
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 35
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 34
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 34
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 34
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 34
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 33
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 31
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 31
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 30
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 30
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 29
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 28
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 28
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 28
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 28
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 27
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 26
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 26
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 25
OncoAlert round table discussions: The global COVID-19 experience 23
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 23
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 21
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 19
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 18
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 18
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 18
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 18
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 17
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 17
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 16
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 16
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 15
Response prediction to EGFR-targeted therapies in colorectal cancer 13
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 13
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 11
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 11
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells 11
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 11
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 11
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 10
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib : does intratumoral heterogeneity matter? 9
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 9
Totale 3.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 0 3 6
2020/2021760 3 5 6 4 23 230 118 46 134 95 10 86
2021/2022553 15 8 2 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/202568 46 22 0 0 0 0 0 0 0 0 0 0
Totale 3.795